<DOC>
	<DOCNO>NCT00650637</DOCNO>
	<brief_summary>The purpose study determine efficacy safety calcium carbonate prevention nelfinavir-associated diarrhea evaluate efficacy safety calcium carbonate combination loperamide treatment nelfinavir-associated diarrhea .</brief_summary>
	<brief_title>A Study Determine Effective Prophylaxis Treatment Nelfinavir-Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Antiretroviralnaive patient HIV1 infection 2 loose stool per day preexist emerge medical condition would interfere evaluation therapeutic response study drug No antidiarrheal medication within 7 day prior entry Greater equal 2 loose stool per day last 2 day within 7 day prior study entry Bloody stool within 7 day prior study entry Any unstable severe intercurrent medical condition , include active opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>